Welcome to Lawsuit.com  

Our mission is to provide each client with the most effective ethical representation possible, and to preserve and promote the civil justice system.

Caution on Baraclude Therapy for Certain HBV Patients

Posted on April 29, 2008

Bristol-Myers Squibb has notified healthcare professionals about a new boxed warning for the antiviral drug Baraclude (entecavir). Baraclude is approved to treat certain patients with chronic hepatitis B.

The boxed warning says that patients infected with both hepatitis B virus and HIV who are being treated with Baraclude for their hepatitis can develop resistance to certain HIV drugs unless the HIV infection is treated at the same time. Because of this, Baraclude is not recommended for HBV patients who also have HIV unless they're receiving highly active antiretroviral therapy.

The labeling also says that patients should be offered HIV antibody testing before starting Baraclude therapy. They should be told that if they have HIV and are not being treated for it, taking Baraclude could increase the chance of their becoming resistant to certain HIV medications.

Additional Information:

FDA MedWatch Safety Alert. Baraclude (entecavir) Tablets and Oral Solution. August 16, 2007.
http://www.fda.gov/medwatch/safety/2007/safety07.htm#Baraclude

Lawsuit Membership
Law firms interested in becoming part of this unique legal community should apply here.Join Lawsuit.com

Lawsuit Video Tips
To become a participating member of Lawsuit.com you must supply a video about your firm, talk about the litigation you find important, and how you help your clients. For ideas and video tips on effective videos click here. Video Creation Tips

Become an Editor
Lawsuit.com is currently building one of the largest human-edited legal video databases in the Web 2.0 World. Want to help? Apply here to become an Editor.Comment